Photocure Expands Hexvix Access Through Clinigen Deal
Photocure ASA and Clinigen have agreed to supply the bladder cancer imaging agent Hexvix globally under a Named Patient Program.
Updated on Nov. 18, 2026 in Cancer

Photocure ASA entered into an agreement with Clinigen for global supply of Hexvix under a Named Patient Program. The program will start in over 40 markets where Hexvix is not yet approved or commercially available.
Why it matters
The program is designed to broaden access to blue light cystoscopy for bladder cancer patients who would otherwise be unable to benefit from it. Physicians can prescribe Hexvix for individual patients in countries where the product is not approved or marketed.
Bladder cancer ranks as the 6th most common cancer worldwide, with approximately 635,000 new cases and 227,000 deaths recorded in 2024, and about 75% of cases occurring in men. The announcement does not specify which of the 40-plus markets will receive access first or how quickly the program will expand.
The players
Photocure ASA
Photocure ASA is a Norwegian biopharmaceutical company, headquartered in Oslo, that develops and commercializes photodynamic diagnosis and therapy products.
Clinigen
Clinigen is a global specialty pharmaceutical company that provides access to medicines in countries where they are not commercially available, operating in about 130 countries.
The details
Under the Named Patient Program, a physician determines whether a bladder cancer patient may benefit from blue light cystoscopy using Hexvix/Cysview and prescribes the product in accordance with local laws. Clinigen will handle worldwide distribution from a central warehouse in the UK, with dedicated local-language speakers supporting the supply.
Timeline
2024: Initial Named Patient Program set up in South Africa.
November 18, 2026: Photocure and Clinigen announce the Named Patient Program agreement.
Access Pathway
The arrangement follows the Named Patient Program model that Clinigen uses to supply medicines in countries without commercial approval, extending that approach to a diagnostic imaging agent for bladder cancer. It builds on the 2024 South Africa setup as a template for scaling access across more than 40 markets.
Patients with bladder cancer in participating markets may be able to access blue light cystoscopy with Hexvix if their physician determines it could benefit them. Access will depend on local laws and whether a prescribing physician chooses to use the program.
The takeaway
Expanded access to diagnostic tools like Hexvix can help more patients benefit from advanced bladder cancer detection. Patients should discuss with their physicians whether blue light cystoscopy is appropriate for their care.
Further reading
Explore more on Cancer developments and treatment access worldwide.
Source note: This article includes information reported by Firstwordpharma.



